Valuation
P/E Ratio -15,42x
P/B Ratio 5,39x
P/S Ratio —
P/FCF Ratio —
Margins
Gross Margin 89,03 %
Operating Margin -47,36 %
Net Margin -56,03 %
KINDRED BIOSCIENCES INC Share · US4945771099 · KIN · A1XA6K (XNCM) United States · Healthcare — real-time prices and quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of KINDRED BIOSCIENCES INC
No Price
Invested Funds
The following funds have invested in KINDRED BIOSCIENCES INC:
Fund | Vol. in million 48,23 | Percentage (%) 0,33 % |
Fund | Vol. in million 318,96 | Percentage (%) 0,04 % |
Fund | Vol. in million 615,40 | Percentage (%) 0,02 % |
Fund | Vol. in million 10,34 | Percentage (%) 0,0031 % |
Fund | Vol. in million 0,46 | Percentage (%) 0,00 % |
Company Profile for KINDRED BIOSCIENCES INC Share
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
Company Data
Name KINDRED BIOSCIENCES INC
Company Kindred Biosciences, Inc.
Symbol KIN
Website
http://www.kindredbio.com
Primary Exchange 
NASDAQ CAPITAL MARKET
NASDAQ CAPITAL MARKET
WKN A1XA6K
ISIN US4945771099
Asset Class Share
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Richard Chin
Country United States
Currency USD
Employees 0,1 T
Address 1555 Bayshore Hwy Ste 200, 94010 Burlingame
IPO Date 2013-12-12
Key Ratios
As of 03.07.2026
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | KIN |
More Shares
Investors who hold KINDRED BIOSCIENCES INC also have the following shares in their portfolio:
